
## Dirk O Bauerschlag

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1512845/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity <i>In Vitro</i> and <i>In Vivo</i> . Molecular Cancer Therapeutics, 2022, 21, 70-78.	1.9	1
2	High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer. Cancers, 2022, 14, 2.	1.7	6
3	A Giant Mammary Hamartoma in a Young Breast Cancer Patient. Breast Care, 2021, 16, 85-88.	0.8	2
4	Involvement of medical students in aÂsurgery congress: impact on learning motivation, decision-making for aÂcareer in surgery, and educational curriculum. Wiener Medizinische Wochenschrift, 2021, 171, 182-193.	0.5	3
5	ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids. Cancers, 2021, 13, 2039.	1.7	17
6	Mucinous Cystic Neoplasm of Pancreas in a Pregnant Woman Presenting with Severe Anemia and Gastric Bleeding: Case Report and Review of the Literature. Healthcare (Switzerland), 2021, 9, 540.	1.0	2
7	Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clinical and Translational Radiation Oncology, 2021, 28, 90-96.	0.9	14
8	Challenges and Controversies in the Surgical Treatment of Cervical Cancer: Open Radical Hysterectomy versus Minimally Invasive Radical Hysterectomy. Journal of Clinical Medicine, 2021, 10, 3761.	1.0	5
9	ADAM17—A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer. Cancers, 2021, 13, 5563.	1.7	11
10	Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	1.4	3
11	Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. Journal of Leukocyte Biology, 2020, 107, 1081-1095.	1.5	35
12	Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses Î <sup>3</sup> δT Cell Proliferation but Not Their Cytotoxicity. Frontiers in Immunology, 2020, 11, 1328.	2.2	16
13	ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany. Breast Care, 2019, 14, 401-408.	0.8	4
14	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-Cancer Drugs, 2019, 30, 394-401.	0.7	3
15	SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. Oncotarget, 2019, 10, 6494-6508.	0.8	19
16	RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue. Oncotarget, 2018, 9, 32362-32372.	0.8	1
17	Quantifying cell free DNA in urine: comparison between commercial kits, impact of gender and inter-individual variation. BioTechniques, 2018, 64, 225-230.	0.8	31
18	Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1785-1792.	1.2	69

#	Article	IF	CITATIONS
19	Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδT Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. Frontiers in Immunology, 2018, 9, 814.	2.2	84
20	ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget, 2018, 9, 16043-16058.	0.8	17
21	Detection and Specific Elimination of EGFR+ Ovarian Cancer Cells Using a Near Infrared Photoimmunotheranostic Approach. Pharmaceutical Research, 2017, 34, 696-703.	1.7	20
22	Serum cholesterol acceptor capacity in intrauterine growth restricted fetuses. Journal of Perinatal Medicine, 2017, 45, 829-835.	0.6	8
23	Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer. Transfusion Medicine and Hemotherapy, 2017, 44, 303-310.	0.7	10
24	Integration and Validation of Hysteroscopy Simulation in the Surgical Training Curriculum. Journal of Surgical Education, 2017, 74, 84-90.	1.2	23
25	The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application. Archives of Gynecology and Obstetrics, 2016, 294, 889-895.	0.8	11
26	A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1003-1011.	1.2	29
27	Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand. Oncotarget, 2016, 7, 54925-54936.	0.8	24
28	Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. Journal of Translational Medicine, 2015, 13, 146.	1.8	95
29	Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer. Oncology, 2014, 87, 300-310.	0.9	16
30	Standard of Care and Controversies in the Adjuvant Endocrine Treatment of Hormone-Responsive Early Breast Cancer. Breast Care, 2014, 9, 283-286.	0.8	7
31	Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. European Journal of Radiology, 2014, 83, 463-467.	1.2	20
32	Fulminant puerperal sepsis due to anaplastic large-cell lymphoma (ALCL) with therapy-refractory cerebral edema. Archives of Gynecology and Obstetrics, 2014, 290, 191-193.	0.8	0
33	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2047-2056.	1.2	28
34	Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary. Journal of Cancer Research and Clinical Oncology, 2013, 139, 347-355.	1.2	5
35	Evaluation of Potentially Predictive Markers for Anti-Angiogenic Therapy with Sunitinib in Recurrent Ovarian Cancer Patients. Translational Oncology, 2013, 6, 305-310.	1.7	12
36	Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group. Geburtshilfe Und Frauenheilkunde, 2013, 73, 433-439.	0.8	4

DIRK O BAUERSCHLAG

#	Article	IF	CITATIONS
37	A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Annals of Oncology, 2012, 23, 2265-2271.	0.6	72
38	Maternal and fetal cord blood lipids in intrauterine growth restriction. Journal of Perinatal Medicine, 2012, 40, 287-96.	0.6	68
39	Primary Pulmonary Choriocarcinoma: Case Report and Review of the Literature. Gynecologic and Obstetric Investigation, 2012, 74, 171-176.	0.7	35
40	The Evaluation of the Oxidative State of Low-Density Lipoproteins in Intrauterine Growth Restriction and Preeclampsia. Hypertension in Pregnancy, 2012, 31, 156-165.	0.5	41
41	Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer. Oncology Letters, 2012, 3, 530-534.	0.8	10
42	Massive Respiratory Dysfunction as Sign of Fulminant Peripartum Cardiomyopathy (PPCM). Hypertension in Pregnancy, 2012, 31, 451-453.	0.5	6
43	Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 603-610.	1.2	10
44	Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles. Oncology, 2011, 80, 12-20.	0.9	43
45	Combined treatment with TRAIL and PPARÎ <sup>3</sup> ligands overcomes chemoresistance of ovarian cancer cell lines. Journal of Cancer Research and Clinical Oncology, 2011, 137, 875-886.	1.2	26
46	Leiomyomatosis peritonealis disseminata in a pregnant woman. Archives of Gynecology and Obstetrics, 2010, 281, 123-127.	0.8	9
47	The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2010, 136, 79-88.	1.2	8
48	In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer, 2010, 10, 412.	1.1	47
49	Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Research, 2010, 30, 3355-60.	0.5	17
50	One-step nucleic acid amplification—a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 203-210.	1.4	100
51	Early detection of a twin tubal pregnancy by Doppler sonography allows fertility-conserving laparoscopic surgery. Archives of Gynecology and Obstetrics, 2009, 279, 87-90.	0.8	9
52	Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling. Cancer Letters, 2009, 273, 70-79.	3.2	28
53	Combination of Enzastaurin and Pemetrexed Inhibits Cell Growth and Induces Apoptosis of Chemoresistant Ovarian Cancer Cells Regulating Extracellular Signal-Regulated Kinase 1/2 Phosphorylation. Translational Oncology, 2009, 2, 164-IN1.	1.7	12
54	Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1397-1405.	1.2	26

DIRK O BAUERSCHLAG

#	Article	IF	CITATIONS
55	Anti-idiotypic antibody abagovomab in advanced ovarian cancer. Future Oncology, 2008, 4, 769-773.	1.1	3
56	An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma. Clinical Cancer Research, 2007, 13, 458-466.	3.2	48
57	Familial Breast Cancer, Prevention, Risk Factors and Genetics – Highlights from the San Antonio Breast Cancer Symposium (SABCS) Poster Presentations. Breast Care, 2006, 1, 103-106.	0.8	Ο
58	Benign abdominal and pulmonary metastasizing leiomyoma of the uterus. Archives of Gynecology and Obstetrics, 2006, 274, 319-322.	0.8	40
59	Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene, 2005, 24, 1053-1065.	2.6	182
60	Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi. Seminars in Cancer Biology, 2003, 13, 293-300.	4.3	17